* High rates of durable hematological response and symptom control with good tolerability were reconfirmed with Ropeginterferon alfa-2b after 36 months of treatment. [more]
10°
10°
10°
8°
1°
4°
0°
© 
SCIENCE TOP STORY
Mon, 2018-12-03 - 19:30
* High rates of durable hematological response and symptom control with good tolerability were reconfirmed with Ropeginterferon alfa-2b after 36 months of treatment.
SCIENCE
1 2 3 4 5 6 7 … 66 67 Next »
Free publishing of limited news hosted permanently on newsfox. Submit releases and have them appeared on newsfox and search engines.
Flat rate: 750 Euro per year
Flat rate: 750 Euro per year
Distribute your press releases in realtime to more than 250.000 journalists, decision makers, investors and PR professionals and more than 60.000 financial experts via pressetext and its news distribution partners throughout Europe, the Americas and Asia.
Single relase from 330 Euro
Packages from 2.400 Euro
Single relase from 330 Euro
Packages from 2.400 Euro
